GEN News Highlights: Jan 19, 2012

Sartorius Stedim, G-Con Partner to Offer Self-Contained Biomanufacturing Facilities

(Page 1 of 1)

    Sartorius Stedim Biotech and G-Con manufacturing have established a global collaboration to offer production platforms for biomanufacturing. The resulting product line will combine G-Con’s modular, mobile cleanroom pods with Sartorius Stedim’s single-use and reusable product portfolio, to generate an integrated production process platform that will be available as plug-and-pay tools for manufacturing facilities. Sartorius Stedim says it has incorporated its products into unit operations for media/buffer preparation, seed fermentation, cell cultivation and harvesting, ultra-diafiltration, membrane chromatography, and viral clearance for biopharma development and manufacturing.

    “Our integrated solutions unit will complement G-Con’s platform of modular cleanroom systems into their designs," explains Maik Jornitz, Sartorius Stem Biotech’s svp of marketing for bioprocess solutions. “Our vision is to create standardized unit operations, implemented into the self-contained G-Con modules. These modules can be used as individual process units or joined to an entire process.”

    G-Con’s portable cleanroom module is a walk-in biological safety cabinet that can be sized to accommodate most upstream and downstream bioprocessing activities, and clustered to provide all necessary environments for bioprocessing and pharmaceutical manufacturing. The modules are completely self-contained for mechanical services and rely only on centralized chilled water and electricity.

    The firm has already worked with firms and organizations including including Icon Genetics, Gradalis, and the Baylor Research Institute, on projects for the design and/or construction of facilities for the production of monoclonal antibodies, dendtritic cell-based cancer vaccines, and cell-based therapeutics. 


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll